Pharmafile Logo
Pharmafocus logo
Advanced Search

Vamorolone

Showing 2 posts of 2 posts found.

Santhera closes exclusive license agreement with Catalyst Pharmaceuticals for Vamorolone

July 19, 2023
Medical Communications License Agreement, Musculo-skeletal disorder, Vamorolone, catalyst, santhera

Santhera Pharmaceuticals has announced the closing of its exclusive North American license agreement for vamorolone with Catalyst Pharmaceuticals. The agreement …

News

Santhera and Catalyst Pharmaceuticals sign $231m license and collaboration deal

June 20, 2023
Medical Communications Catalyst Pharmaceuticals, Rare Diseases, Vamorolone, licence and collaboration, santhera

Swiss specialty pharmaceutical company Santhera and US-based biopharmaceutical company Catalyst Pharmaceuticals have announced that they have signed an exclusive license …

News
The Gateway to Local Adoption Series

Latest content

Pharma sees climate disruption as growing supply-chain risk

September 11, 2026

Manchester NHS-MHRA partnership to test new technologies in real-world care

September 10, 2026

Ondine reports 40% reduction in surgical-site infections in phase 3 trial

September 9, 2026

Northern Ireland to roll out staff well-being training across health service

September 8, 2026

European consortium demonstrates continuous manufacturing platform for pharmaceutical ingredients

September 7, 2026